BioNexus Chooses Ethereum Over Bitcoin for Treasury Strategy

On March 5, 2025, BioNexus Gene Lab, located in Malaysia, made pivotal news by announcing its decision to prioritize Ethereum (ETH) over Bitcoin (BTC)

BioNexus Gene Lab (Nasdaq:BNXS), a publicly listed company based in Malaysia and focused on gene technology, has made the strategic decision to prioritize allocating its treasury assets into Ethereum (ETH) over Bitcoin (BTC).

This decision, announced on March 5, 2025, positions BioNexus as potentially the first Nasdaq-listed institution to adjust its treasury strategy toward a primary holding of a blockchain asset.

The institution’s internal analysis, approved by its Board of Directors, identified several factors influencing their choice of Ethereum. Among these was the U.S. administration’s decision to include ETH in the government’s Crypto Strategic Reserve.

Another key factor was the potential for staking on Ethereum, which allows companies to generate additional yields of 3% to 5% annually, in contrast to Bitcoin which is traditionally used as a store of value.

“Ethereum offers high liquidity, utility, and stability compared to other digital assets, positioning BGLC as a leader in blockchain-integrated corporate finance,” said Sam Tan, CEO of BioNexus.

The company, which had a market cap of $6 million, revenue of $2.6 million, and net income of negative $1.3 million as of September 30, 2024, is optimistic about this strategic pivot.

This decision also follows the creation of a favorable regulatory environment for blockchain businesses in Wyoming, with the passing of the “Wyoming Stable Token Act” in March 2023 being particularly relevant.

The Act allows the Wyoming Stable Token Commission to issue tokens that are exchangeable for U.S. dollars, aligning with BioNexus’s innovative, forward-thinking approach.

BioNexus elaborates further on Ethereum’s advantages over Bitcoin in its whitepaper titled “ETH Strategy.” The institution explains how Ethereum serves not only as digital currency but also the settlement layer for various stablecoins like Tether USD (USDT) and USD Coin (USDC).

The system handles vast transaction volumes, reported as trillions of dollars annually, bolstering its role as central to the burgeoning digital economy.

Moreover, the whitepaper delves into how Ethereum’s capabilities, spanning tokenization of financial assets, decentralized payments, and enhanced regulatory compliance, render it especially appealing to banks, investment firms, and publicly traded companies. These institutions are increasingly adopting Ethereum as a component of their financial architectures.

Finally, BioNexus anticipates utilizing Ethereum exchange-traded funds (ETFs) more frequently, reflecting the growing institutional acceptance of ETH. The institution’s strategy also implies support for the upcoming Ethereum upgrades, with excitement building around the Pectra update scheduled for April 2025.

This update promises to improve wallet functionalities, validator operations, network performance, smart contract deployment, and account abstraction, highlighting its commitment to leveraging Ethereum’s innovation.